Course Listings: Cardiology

All Results (5)
Format: Live Events (0) Online Activities (5)

Renal Implications of Resistant Hypertension

View Course

Format: Med-IQ Express

Maximum Credits: 0.25

Course Description: This brief activity discusses the definition of resistant hypertension (RH) as well as ways to evaluate and assess the condition. In addition, faculty provide insights on current management strategies for patients with both RH and chronic kidney disease.


Duke Perspectives From the American Heart Association Annual Meeting

View Course

Format: PDF Publication

Maximum Credits: 0.5

Course Description: This publication summarizes pertinent new research findings that were presented at the 2018 American Heart Association meeting held November 10 to 12 in Chicago, IL. In addition, Manesh Patel, MD, professor of medicine and chief of the Division of Cardiology provides interesting perspectives on the study results.


Decision-IQ: An Unusual Case of Curable Hypertension

View Course

Format: Decision-IQ

Maximum Credits: 0.25

Course Description: In this short case-based activity, you will meet a 38-year-old man who has been referred to a cardiologist for early onset, refractory hypertension. As you move through this activity, click on the links to review resources to help you make diagnostic and management decisions for this patient, and read insights from cardiologist Richard A. Krasuski, MD, on how…More


GFR and eGFR: Filtering Out the Confusion

View Course

Format: E-Publication

Maximum Credits: 1.0

Course Description: Nephrologist Dr. Michael Wiederkehr delves into chronic kidney disease (CKD) and the difference between true glomerular filtration rate (GFR) and estimated glomerular filtration rate (eGFR). The different methods of calculating eGFR will be explored as well as the pitfalls and limitations of the current formulas and calculations. The importance of the CKD…More


PCSK9 Inhibitors: For Whom, When, and Why

View Course

Format: Audiocast

Maximum Credits: 0.5

Course Description: In this audiocast, expert faculty discuss current clinical evidence regarding the benefit of adding a PCSK9 inhibitor to statin therapy in patients with cardiovascular risk and dyslipidemia. Additionally, key criteria for selecting patients for PCSK9 inhibitor therapy as well as determining optimal timing for initiating treatment are explored.